Nuvation Bio (NUVB) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.15
- Estimate
- -$0.12
- Surprise
- -25.1%
- Revenue (period 2026-06-30)
- $31.7M
- Score at report (before → after)
- 5.3 → 5.2/10
Revenue source: xbrl.
How the report landed
Nuvation Bio (NUVB) reported a wider loss than forecast — diluted EPS of -$0.15 against the -$0.12 estimate (a 25.1% shortfall). TrendMatrix's engine moved from Buy (Wait) (5.3/10) to Sell at 5.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates NUVB Sell at 4.9/10.
1 of the last 4 quarters beat the estimate; this quarter's -25.1% surprise compares with a +565.6% four-quarter average. Next scheduled report: 2026-11-02.
What argues against it
- Concentration risk — Product: IBTROZI (taletrectinib)
- Concentration risk — Counterparty: Daiichi Sankyo (in-license partner)
- Quality below floor (3.9 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.82
- Price target
- $11.40
- Stop
- $6.36
- Upside to target
- +67.2%
- Reward-to-risk
- 4.8:1
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
NUVB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.38B
- P/E (fwd)
- -451.3
- 52-week range
- $2.99–$9.75
- Off 52-week high
- 30.1%
- RSI (14)
- 56
- Volume vs avg
- 0.13×
- Score today
- 4.9/10